

BerGenBio – US Clinical Trial Update

Bergen, Norway, 27 November 2017 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, provides an update on BGBC004, an on-going, company sponsored US study evaluating BGB324 in conjunction with TARCEVA® (erlotinib) in patients with non-small cell lung cancer, in response to recent media coverage.

BerGenBio gained the required approvals from the US Food & Drug Administration (FDA) and from the ethics committees at the participating US hospitals prior to starting this study with BGB324. BerGenBio can confirm that it is in discussions with the Regional Ethics Committee (REK) in Bergen and the Norwegian Board of Health to gain retrospective approval to conduct the BGBC004 study in the US.

- Ends -

Contact

Richard Godfrey

CEO, BerGenBio ASA

+47 917 86 304

Tom Henrik Sundby

Finance Director, BerGenBio ASA

tom.sundby@bergenbio.com

+47 477 54 415

Media Relations

David Dible, Mark Swallow, Marine Perrier

Citigate Dewe Rogerson

bergenbio@citigatedewerogerson.com

+44 207 638 9571